Dr. Deepak K. Gupta, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 239
Licensed in Vermont since 2018, according to the Vermont Board of Medical Practice. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NY license 284526 · VT license 042.0014005 (first issued 2018; active in renewal) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Univ. of Vermont - Fletcher Allen Health Care Burlington, VT
- The University of Vermont Health Network - Champl Plattsburgh, NY
- Northwestern Medical Center Inc Saint Albans, VT
Medical groups
- University of Vermont Medical Center Inc (1,208 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 239
- Services billed
- 759
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 10-19 minutes | 127 | 91 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 83 | 30 |
| Established patient office or other outpatient visit, 20-29 minutes | 62 | 53 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 56 | 18 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 35 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 27 | 26 |
| Established patient office or other outpatient visit, 40-54 minutes | 24 | 23 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 23 | 11 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 16 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in New York, NY | 368 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in New York, NY | 157 |
| Amantadine (amantadine hcl) Other prescribers in New York, NY | 65 |
| Donepezil Hcl Other prescribers in New York, NY | 52 |
| Pramipexole Dihydrochloride (pramipexole di-hcl) Other prescribers in New York, NY | 39 |
| Rasagiline Mesylate | 35 |
| Primidone Other prescribers in New York, NY | 34 |
| Selegiline Hcl | 27 |
| Rytary (carbidopa/levodopa) Other prescribers in New York, NY | 27 |
| Ingrezza (valbenazine tosylate) Other prescribers in New York, NY | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $14.08 in total to this clinician.
| Glaukos Corporation | $14.08 |
|---|
| Food and Beverage | $14.08 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $8,039 in research payments for these studies, mostly to the institutions running them.
- Fixed-Dose Trial in Early Parkinson's Disease (PD)
AbbVie Inc. · Completed · NCT04201093
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.